Janney Montgomery Scott LLC Has $1.77 Million Stock Position in Insulet Co. (NASDAQ:PODD)

Janney Montgomery Scott LLC lifted its position in Insulet Co. (NASDAQ:PODD – Get Rating) by 17.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,717 shares of the medical instruments supplier’s stock after buying an additional 1,142 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Insulet were worth $1,770,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of PODD. Clearbridge Investments LLC lifted its stake in shares of Insulet by 38.8% in the first quarter. Clearbridge Investments LLC now owns 1,696,822 shares of the medical instruments supplier’s stock worth $452,016,000 after buying an additional 474,545 shares during the last quarter. Renaissance Technologies LLC increased its position in Insulet by 106.9% during the first quarter. Renaissance Technologies LLC now owns 182,900 shares of the medical instruments supplier’s stock worth $48,723,000 after acquiring an additional 94,500 shares during the period. Vanguard Group Inc. increased its position in Insulet by 1.0% during the first quarter. Vanguard Group Inc. now owns 6,203,941 shares of the medical instruments supplier’s stock worth $1,652,668,000 after acquiring an additional 58,932 shares during the period. Point72 Asset Management L.P. bought a new position in Insulet during the second quarter worth $10,428,000. Finally, Worldquant Millennium Advisors LLC bought a new position in Insulet during the first quarter worth $8,662,000.

Insiders Place Their Bets

In other news, Director Shacey Petrovic sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 4th. The shares were sold at an average price of $281.88, for a total transaction of $4,228,200.00. Following the transaction, the director now directly owns 14,789 shares in the company, valued at $4,168,723.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Shacey Petrovic sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 4th. The shares were sold at an average price of $281.88, for a total transaction of $4,228,200.00. Following the transaction, the director now directly owns 14,789 shares in the company, valued at $4,168,723.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael P. Spears sold 13,658 shares of the company’s stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $308.99, for a total transaction of $4,220,185.42. Following the transaction, the senior vice president now owns 8,792 shares in the company, valued at $2,716,640.08. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,858 shares of company stock valued at $8,507,309. Insiders own 0.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on PODD. Canaccord Genuity Group boosted their target price on shares of Insulet from $290.00 to $310.00 and gave the stock a “buy” rating in a research report on Friday, November 4th. Barclays boosted their target price on shares of Insulet from $238.00 to $245.00 in a research report on Wednesday, January 4th. StockNews.com raised shares of Insulet from a “sell” rating to a “hold” rating in a report on Wednesday, November 9th. Citigroup boosted their price target on shares of Insulet from $270.00 to $330.00 in a report on Monday, December 12th. Finally, Morgan Stanley boosted their price target on shares of Insulet from $300.00 to $320.00 and gave the company an “equal weight” rating in a report on Friday, January 6th. Five research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $309.23.

Insulet Stock Down 0.1 %

Shares of NASDAQ:PODD opened at $305.89 on Friday. Insulet Co. has a 52 week low of $181.00 and a 52 week high of $320.00. The company has a debt-to-equity ratio of 3.22, a quick ratio of 3.00 and a current ratio of 3.98. The company’s fifty day moving average is $297.60 and its 200-day moving average is $264.76. The company has a market capitalization of $21.24 billion, a PE ratio of 1,274.54 and a beta of 0.79.

Insulet (NASDAQ:PODD – Get Rating) last issued its earnings results on Thursday, November 3rd. The medical instruments supplier reported $0.45 EPS for the quarter, beating the consensus estimate of $0.17 by $0.28. The company had revenue of $340.80 million for the quarter, compared to the consensus estimate of $311.84 million. Insulet had a net margin of 1.35% and a return on equity of 18.19%. Equities research analysts predict that Insulet Co. will post 0.87 earnings per share for the current fiscal year.

Insulet Company Profile

(Get Rating)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.